Atai Life Sciences

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions.[1][2][3][4][5] It was founded in 2018 and is headquartered in Berlin, Germany.[1][5]

The company's pharmaceutical candidates include dimethyltryptamine (DMT; VLS-01; oromucosal film), (R)-midomafetamine ((R)-MDMA; EMP-01), and ibogaine (IBX-210, DMX-1002), as well as EGX-121 (a non-tryptamine new chemical entity), 5-MeO-DMT (BPL-003; intranasal), psilocin (ELE-101), inidascamine (RL-007), deuterated mitragynine (KUR-101), EGX-A, EGX-B, deuterated etifoxine (GRX-917), and arketamine (PCN-101).[4][3][6]

In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange.[1][7] In January 2023, atai Life Science's leading drug candidate at the time, arketamine (PCN-101), failed to meet its primary endpoint in a clinical trial.[1] Following that, the company laid off 30% of its staff.[1]

Peter Thiel is a major investor in the company.[1] atai Life Sciences has a 22.4% stake in Compass Pathways.[1][5]

See also

• List of psychedelic pharmaceutical companies
• List of investigational hallucinogens and entactogens

External links